Dataset Information

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer.

ABSTRACT:

Background

Cell free RNA (cfRNA) contains transcript fragments from multiple cell types, making it useful for cancer detection in clinical settings. However, the pathophysiological origins of cfRNAs in plasma from colorectal cancer (CRC) patients remain unclear.

Methods

To identify the tissue-specific contributions of cfRNAs transcriptomic profile, we used a published single-cell transcriptomics profile to deconvolute cell type abundance among paired plasma samples from CRC patients who underwent tumor-ablative surgery. We further validated the differentially expressed cfRNAs in 5 pairs of CRC tumor samples and adjacent tissue samples as well as 3 additional CRC tumor samples using RNA-sequencing.

Results

The transcriptomic component from intestinal secretory cells was significantly decreased in the in-house post-surgical cfRNA. The HPGD, PACS1, and TDP2 expression was consistent across cfRNA and tissue samples. Using the Cancer Genome Atlas (TCGA) CRC datasets, we were able to classify the patients into two groups with significantly different survival outcomes.

Conclusions

The three-gene signature holds promise in applying minimal residual disease (MRD) testing, which involves profiling remnants of cancer cells after or during treatment. Biomarkers identified in the present study need to be validated in a larger cohort of samples in order to ascertain their possible use in early diagnosis of CRC.

SUBMITTER: Jin N

PROVIDER: S-EPMC10115432 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer.

Jin Nana N Kan Chau-Ming CM Pei Xiao Meng XM Cheung Wing Lam WL Ng Simon Siu Man SSM Wong Heong Ting HT Cheng Hennie Yuk-Lin HY Leung Wing Wa WW Wong Yee Ni YN Tsang Hin Fung HF Chan Amanda Kit Ching AKC Wong Yin Kwan Evelyn YKE Cho William Chi Shing WCS Chan John Kwok Cheung JKC Tai William Chi Shing WCS Chan Ting-Fung TF Wong Sze Chuen Cesar SCC Yim Aldrin Kay-Yuen AK Yu Allen Chi-Shing AC

Frontiers in oncology 20230405

<h4>Background</h4>Cell free RNA (cfRNA) contains transcript fragments from multiple cell types, making it useful for cancer detection in clinical settings. However, the pathophysiological origins of cfRNAs in plasma from colorectal cancer (CRC) patients remain unclear.<h4>Methods</h4>To identify the tissue-specific contributions of cfRNAs transcriptomic profile, we used a published single-cell transcriptomics profile to deconvolute cell type abundance among paired plasma samples from CRC patien ...[more]

PMID: 37091184

Similar Datasets

Project description:ImportanceFor patients with resected, nonmetastatic colorectal cancer (CRC), the optimal surveillance protocol remains unclear.ObjectiveTo evaluate whether serial circulating tumor DNA (ctDNA) levels detected disease recurrence earlier, compared with conventional postoperative surveillance, in patients with resected CRC.Design, setting, and participantsThis study included patients (n = 58) with stage I, II, or III CRC who underwent radical surgical resection at 4 Swedish hospitals from February 2, 2007, to May 8, 2013. Eighteen patients received adjuvant chemotherapy at the discretion of their clinicians, who were blinded to the ctDNA results. Blood samples were collected at 1 month after the surgical procedure and every 3 to 6 months thereafter for ctDNA analysis. Patients were followed up until metachronous metastases were detected, or for a median of 49 months. Data analysis was performed from March 1, 2009, to June 23, 2018.Main outcomes and measuresSensitivity and timing of ctDNA positivity were compared with those of conventional surveillance modalities (computed tomographic scans and serum carcinoembryonic antigen tests) for the detection of disease recurrence.ResultsThis study included 319 blood samples from 58 patients, with a median (range) age of 69 (47-83) years and 34 males (59%). The recurrence rate among patients with positive ctDNA levels was 77% (10 of 13 patients). Positive ctDNA preceded radiologic and clinical evidence of recurrence by a median of 3 months. Of the 45 patients with negative ctDNA throughout follow-up, none (0%; 95% CI, 0%-7.9%) experienced a relapse, with a median follow-up of 49 months. However, 3 (6%; 95% CI, 1.3%-17%) of the 48 patients without relapse had a positive ctDNA result, which subsequently fell to undetectable levels during follow-up.Conclusion and relevanceAlthough these findings need to be validated in a larger, prospective trial, they suggest that ctDNA analysis could complement conventional surveillance strategies as a triage test to stratify patients with resected CRC on the basis of risk of disease recurrence.

Dataset Information

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer.

Background

Methods

Results

Conclusions

Publications

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets